Articles
Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors. Read More ›
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa. Read More ›
By Phoebe Starr
Real-world experience at the University of Texas M.D. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis. Read More ›
By Phoebe Starr
The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. Read More ›
Compliance with orders for granulocyte colony-stimulating factors (G-CSFs) is suboptimal, and inadequate prophylaxis was directly tied to hospital admissions, according to results of a recent clinical trial from the University of Pennsylvania Health System. Read More ›
- Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
- Lay Navigation Reduces Medicare Costs, Resource Utilization
- Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer
A pharmacist-led outreach program at Magellan Rx Management improved adherence to tyrosine kinase inhibitors (TKIs), and compliance with polymerase chain reaction (PCR) testing in patients with chronic myeloid leukemia (CML). Read More ›
By Wayne Kuznar
By improving chemotherapy-induced peripheral neuropathy (CIPN), administration of duloxetine may enable patients with advanced pancreatic cancer to continue their treatment regimen of gemcitabine plus nab-paclitaxel. Read More ›
By Chase Doyle
Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations. Read More ›
By Chase Doyle
When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions. Read More ›